Peptide Receptor Radionuclide Therapy improves progression free and overall survival in patients who progress after resection of gastroenteropancreatic NETs

#4094

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) improves progression-free-survival (PFS) in advanced midgut neuroendocrine tumors (NETs). Whether PRRT specifically improves survival in surgically managed gastroenteropancreatic (GEP) NET with progression is unknown.

Aim(s): To evaluate PFS and overall-survival (OS) in patients progressing after surgery treated by PRRT vs other therapies.

Materials and methods: We identified patients from our clinic who had resection/cytoreduction of GEP-NET, then disease progression by RECIST 1.1. Kaplan-Meier method assessed PFS and OS, calculated from progression after surgery (no-PRRT group) or start of PRRT. Cox regression with time-dependent covariates controlled for immortal time bias and other confounders.

Conference:

Presenting Author: Howe J

Authors: Borbon L, Sherman S, Breheny P, Ear P, Menda Y,

Keywords: gastroenteropancreatic, resection, progression, PRRT, neuroendocrine tumor,